Florida is currently home to 3780 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Recruiting
The purpose of this study is to examine small vessel disease (a condition in which the small arteries in the heart become narrowed). The investigators want to know how the small vessel disease contributes to pre-HFpEF (a condition with inadequate heart muscle function in the setting of preserved muscle pumping) and to better identify potential treatment for prevention of HFpEF. The main procedures of this study include up to 2 clinic visits (initial visit and a second clinical visit only if part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Coronary Microvascular Dysfunction
Lung EpiCheck Biomarkers Development Study
Recruiting
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
02/08/2024
Locations: Life Spring Clinical Research, Miami, Florida
Conditions: Lung Cancer
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Recruiting
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown further reductions in heart failure hospitalization, cardiovascular events, and mortality, especially for heart failure patients. The SGLT2 gene, also known as SLC5A2 (solute carrier family 5 member 2), is located on chromosome 16 and is responsible for encoding SGLT2. Several SLC5A2 mutations alter SGLT2 expression, membrane location, or transporter function. Several common genetic variations were found in the SLC5A2 gene that may... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/06/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Genetic Polymorphisms, Heart Failure
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Recruiting
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/06/2024
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: CLL/SLL
Hyperbaric Oxygen Brain Injury Treatment Trial
Recruiting
The purpose of this innovative adaptive phase II trial design is to determine the optimal combination of hyperbaric oxygen treatment parameters that is most likely to demonstrate improvement in the outcome of severe TBI patients in a subsequent phase III trial.
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
02/06/2024
Locations: St. Mary's Medical Center, West Palm Beach, Florida
Conditions: Traumatic Brain Injury
Baby 2 Baby Beneficial Bacteria
Recruiting
The investigators will recruit mother-infant dyads to attend weekly lactation support groups and randomize infants to receive either an HMO consuming or non-HMO consuming probiotic. The investigators will collect infant stool before and after support group attendance. The investigators will use qPCR and metagenomic sequencing to test if the study probiotics or other bacteria transmit between infants. The investigators anticipate HMO consuming bacteria will and non-HMO consuming bacteria will not... Read More
Gender:
ALL
Ages:
Between 18 years and 62 years
Trial Updated:
02/05/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Transmission
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 02, Sarasota, Florida
Conditions: Breast Cancer
Symbiotic Use in Post-Bariatric Surgery Patients
Recruiting
The purpose of this double blind, randomized control trial would be to test the efficacy of a once daily, multi strain symbiotic on gut health changes in weight loss surgery patients by testing stool samples prior to administration and then three months post administration of the symbiotic to monitor any changes in bacteria in the stool samples. Study participants will also complete a survey that evaluates their bowel habits, stool consistency, and gastrointestinal related symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: University of North Florida, Jacksonville, Florida
Conditions: Bariatric Surgery Candidate
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Boca Raton Clinical Research (BRCR), Boca Raton, Florida
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
The Acute Burn ResUscitation Multicenter Prospective Trial
Recruiting
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: University of Florida Health, Gainesville, Florida
Conditions: Burn Injury
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Sensory Intervention for Children With Autism
Recruiting
Greater than 80% of children with autism spectrum disorder (ASD) experience sensory differences that make it difficult for them to fully participate in meaningful everyday activities. In this research study, we will use MRI and behavioral methods to assess how sensory interventions might change sensory brain structures, allowing us to better predict which sensory interventions might work best for whom.
Gender:
MALE
Ages:
Between 6 years and 9 years
Trial Updated:
01/30/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Autism Spectrum Disorder